Retrieve available abstracts of 122 articles: HTML format
Single Articles
April 2025
WANG J, Zhang S, Fan T, Wu C, et al Letter to the Editor: Association of hepatitis B surface antigen and risk of
hepatocellular carcinoma in chronic hepatitis B patients with immune-tolerant
phase.
Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001365. PubMed
TSENG TC, Kao JH Reply: Association of hepatitis B surface antigen and risk of hepatocellular
carcinoma in chronic hepatitis B patients with immune-tolerant phase.
Hepatology. 2025 Apr 21. doi: 10.1097/HEP.0000000000001366. PubMed
TSENG TC, Lok AS Accurate identification and risk-stratification of HBeAg-negative indeterminate
phase of chronic hepatitis B: not all shades of grey are the same.
Hepatology. 2025 Apr 15. doi: 10.1097/HEP.0000000000001353. PubMed
LUNDBERG BAVE A, von Seth E, Ingre M, Nordenvall C, et al Reply: Primary sclerosing cholangitis and autoimmune hepatitis - distinct or
common autoimmune penetrance?
Hepatology. 2025 Apr 11. doi: 10.1097/HEP.0000000000001326. PubMed
March 2025
GRONBAEK L, Vilstrup H, Jepsen P Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis -
distinct or common autoimmune penetrance?
Hepatology. 2025 Mar 25. doi: 10.1097/HEP.0000000000001325. PubMed
SU R, Tao X, Yan L, Liu Y, et al Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma
in chronic hepatitis B patients based on serum N-glycomics analysis: A cohort
study.
Hepatology. 2025 Mar 21. doi: 10.1097/HEP.0000000000001316. PubMedAbstract available
TSENG TC, Hosaka T, Pan MH, Liu CJ, et al Higher level of Hepatitis B Surface antigen associated with delayed development
of hepatocellular carcinoma in immune-tolerant patients.
Hepatology. 2025 Mar 20. doi: 10.1097/HEP.0000000000001313. PubMedAbstract available
ZHANG T, Huang CJ, Chen HT, Huang YH, et al HLA-DQB1*03:01 and risk of Hepatitis B virus-related hepatocellular carcinoma.
Hepatology. 2025 Mar 14. doi: 10.1097/HEP.0000000000001307. PubMedAbstract available
February 2025
SNIJDERS RJALM, Janik MK, Mund M, Uhlenbusch N, et al Health-related quality of life is impaired in people with autoimmune hepatitis:
Results of a multicentre cross-sectional study within the European Reference
Network.
Hepatology. 2025 Feb 19. doi: 10.1097/HEP.0000000000001271. PubMedAbstract available
WONG GL, Chan HL Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts
required for hepatitis elimination.
Hepatology. 2025 Feb 18. doi: 10.1097/HEP.0000000000001273. PubMed
SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al Long-term outcome and risk stratification in compensated advanced chronic liver
disease after HCV-cure.
Hepatology. 2025;81:609-624. PubMedAbstract available
WEDEMEYER H, Leus M, Battersby TR, Glenn J, et al HDV RNA assays: Performance characteristics, clinical utility, and challenges.
Hepatology. 2025;81:637-650. PubMedAbstract available
January 2025
SHI MA, Pungwe P, Comer LL, Balakrishnan M, et al Corticosteroids in severe alcohol-associated hepatitis? Not so fast: A systematic
review of randomized controlled trials.
Hepatology. 2025 Jan 28. doi: 10.1097/HEP.0000000000001237. PubMedAbstract available
CHEN PC, Deterding K, Engelskircher SA, Port K, et al TIGIT-expression on natural killer cell subsets is an early indicator of
alleviating liver inflammation following bulevirtide treatment in chronic
hepatitis D.
Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001238. PubMedAbstract available
NISHITSUJI H, Naito Y, Murakami Y, Sugiyama M, et al Identification of glycogen synthase kinase 3alpha/beta as a host factor required
for hepatitis B virus transcription using high-throughput screening.
Hepatology. 2025 Jan 23. doi: 10.1097/HEP.0000000000001239. PubMedAbstract available
PATEL K, Asrani SK, Fiel MI, Levine D, et al Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver
disease: A systematic review supporting the AASLD Practice Guideline.
Hepatology. 2025;81:358-379. PubMedAbstract available
December 2024
CHEN KQ, Chen Y, Peng JF, Tang WR, et al Letter to the Editor: Association between hepatitis delta virus with liver
morbidity and mortality: A systematic literature review and meta-analysis.
Hepatology. 2024 Dec 24. doi: 10.1097/HEP.0000000000001210. PubMed
BERETTA M, Vesin B, Wei Y, Planchais C, et al Enhanced hepatitis B virus-specific immunity by combined neutralizing antibody
therapy and DNA vaccination in a murine model of chronic hepatitis B infection.
Hepatology. 2024 Dec 9. doi: 10.1097/HEP.0000000000001179. PubMedAbstract available
JOHN BV, Bastaich D, Dahman B Reply: Association of hepatitis delta virus infection and hepatocellular
carcinoma, hepatic decompensation, all-cause and liver-related death in a
national cohort.
Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001162. PubMed
HE Z, Wang C, Tian H Letter to the editor : Association of hepatitis delta virus infection and
hepatocellular carcinoma, hepatic decompensation, all-cause and liver-related
death in a national cohort.
Hepatology. 2024 Nov 11. doi: 10.1097/HEP.0000000000001159. PubMed
Erratum: Protection and antibody levels 35 years after primary series with
hepatitis B vaccine and response to a booster dose.
Hepatology. 2024;80:E90. PubMed
Erratum: JFH1-based Core-NS2 genotype variants of HCV with genetic stability in
vivo and in vitro: Important tools in the evaluation of virus neutralization.
Hepatology. 2024;80:E86. PubMed
CHUNG Y, IIkay E, Heneghan MA Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on
monitoring metabolite profiles and co-therapy with allopurinol.
Hepatology. 2024;80:1000-1002. PubMed
KEZER CA The ultimate ensemble: Seeing the forest through the trees in alcohol-associated
hepatitis.
Hepatology. 2024;80:995-996. PubMed
MALHI G, Arab JP Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With
Allopurinol.
Hepatology. 2024;80:989-990. PubMed
October 2024
JOHN BV, Bastaich D, Dahman B Reply: Association of hepatitis D virus infection with liver-related outcomes.
Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001142. PubMed
LUO C Letter to the Editor: Association of hepatitis D virus infection with
liver-related outcomes.
Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001140. PubMed
WRANKE A, Wedemeyer H Hepatitis D virus - still the devil !
Hepatology. 2024 Oct 29. doi: 10.1097/HEP.0000000000001144. PubMed
COLPITTS CC, Baumert TF Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1
insertions.
Hepatology. 2024 Oct 22. doi: 10.1097/HEP.0000000000001132. PubMed
OLESEN CH, Collignon L, Velazquez-Moctezuma R, Fanalista M, et al Prevalence of hepatitis C virus hypervariable region 1 insertions and their role
in antibody evasion.
Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001114. PubMedAbstract available
GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al Reply: The causal analysis of missing confounding factors for the association
between HDV and specific liver events.
Hepatology. 2024;80:E50-E52. PubMed
LI Z, Zhang Y, Li Y, Lan J, et al Letter to the Editor: The causal analysis of missing confounding factors for the
association between HDV and specific liver events.
Hepatology. 2024;80:E48-E49. PubMed
SCHNEIDER KM, Kummen M, Trivedi PJ, Hov JR, et al Role of microbiome in autoimmune liver diseases.
Hepatology. 2024;80:965-987. PubMedAbstract available
September 2024
HSU CL, Wang L, Maestri E, Jacob AR, et al Viral antibody response predicts morbidity and mortality in alcohol-associated
hepatitis.
Hepatology. 2024 Sep 25. doi: 10.1097/HEP.0000000000001046. PubMedAbstract available
SONG M, Wang H, Tian X, Gao J, et al TIPE2 protein restrains invariant NKT activation and protects against
immune-mediated hepatitis in mice.
Hepatology. 2024 Sep 25. doi: 10.1097/HEP.0000000000001104. PubMedAbstract available
LIAW YF, Papatheodoridis G Finite nucleos(t)ide-analogue therapy for functional cure in HBeAg-negative
chronic hepatitis B: recent development in the paradigm shift.
Hepatology. 2024 Sep 24. doi: 10.1097/HEP.0000000000001107. PubMedAbstract available
ZHU J, Wu R, Yang T, Yuan Y, et al Harnessing ZIKV NS2A RNA for alleviating acute hepatitis and cytokine release
storm by targeting translation machinery.
Hepatology. 2024 Sep 20. doi: 10.1097/HEP.0000000000001101. PubMedAbstract available
JOHN BV, Bastaich D, Amoli MM, Wong RJ, et al Association of hepatitis delta virus infection and hepatocellular carcinoma,
hepatic decompensation, all-cause and liver-related death in a national cohort.
Hepatology. 2024 Sep 10. doi: 10.1097/HEP.0000000000001092. PubMedAbstract available
EFE C, Lytvyak E, Eskazan T, Liberal R, et al Efficacy and safety of infliximab in patients with autoimmune hepatitis.
Hepatology. 2024 Sep 6. doi: 10.1097/HEP.0000000000001089. PubMedAbstract available
SUN B, da Costa KAS, Alrubayyi A, Kokici J, et al HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC
functional responses.
Hepatology. 2024;80:649-663. PubMedAbstract available
LI Z, Zhang Y, Li Y, Chen X, et al Letter to the Editor: Is the evidence convincing for the expansion of CHB
treatment criteria to reduce the risk of HCC?
Hepatology. 2024;80:E37-E38. PubMed
HUANG DQ, Nguyen MH Reply: Is the evidence convincing for the expansion of CHB treatment criteria to
reduce the risk of HCC?
Hepatology. 2024;80:E39. PubMed
August 2024
ABRAVANEL F, Vignon C, Mercier A, Gaumery JB, et al Large-scale hepatitis E virus genotype 3 outbreak on new caledonia island.
Hepatology. 2024 Aug 30. doi: 10.1097/HEP.0000000000001081. PubMedAbstract available
MCGETTIGAN BM, Osna N Functional humoral immunity is crucial to outcomes in severe alcohol-associated
hepatitis.
Hepatology. 2024 Aug 27. doi: 10.1097/HEP.0000000000001079. PubMed
KHANAM A, Kottilil S Reversal of immune exhaustion for functional cure of chronic hepatitis B: Is the
time right?
Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001059. PubMed
VAN DER MEER AJ, Sonneveld MJ Towards risk-based surveillance for hepatocellular carcinoma after HCV cure?
Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001057. PubMed
STAFYLIS C, Vij AP, Klausner JD Letter to the editor: Bridging the gap between hepatitis C virus diagnosis and
treatment to achieve elimination in the united states.
Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001051. PubMed
GRATACOS-GINES J, Ventura-Cots M, Pose E Reply: Don't forget to discuss TIPS in patients surviving an episode of alcoholic
hepatitis.
Hepatology. 2024 Aug 2. doi: 10.1097/HEP.0000000000001040. PubMed
July 2024
RUDLER M, Bouzbib C, Thabut D To the Editor: Don't forget to discuss TIPS in patients surviving an episode of
alcoholic hepatitis.
Hepatology. 2024 Jul 30. doi: 10.1097/HEP.0000000000001038. PubMed
YUAN Q, Hodgkinson C, Liu X, Barton B, et al Exome-wide association analysis identifies novel risk loci for alcohol-associated
hepatitis.
Hepatology. 2024 Jul 26. doi: 10.1097/HEP.0000000000001027. PubMedAbstract available
PATIDAR KR, Tu W, Cotter TG, Simonetto DA, et al Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra
plus zinc or prednisone.
Hepatology. 2024 Jul 19. doi: 10.1097/HEP.0000000000001019. PubMedAbstract available
QIAN J, Xie Y, Mao Q, Xie Q, et al A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in
virally-suppressed, HBeAg negative chronic hepatitis B patients.
Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001006. PubMedAbstract available
SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al Long-term outcome and risk stratification in compensated advanced chronic liver
disease after HCV-cure.
Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001005. PubMedAbstract available
Erratum: The utility of P-I-R classification in predicting the on-treatment
histological and clinical outcomes of patients with hepatitis B and advanced
liver fibrosis.
Hepatology. 2024;80:E22. PubMed
Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal
transducer and activator of transcription 3 and nitric oxide-dependent impairment
of oxidative DNA repair.
Hepatology. 2024;80:E21. PubMed
June 2024
LAW JL, Drummer HE Bridging the gap: A new tool to down select HCV vaccine candidates.
Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000000948. PubMed
LI J, Ma X, Xuan Q, Li Q, et al Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis
B virus surface antigen particles: Implications for pathobiology of chronic
hepatitis B.
Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000972. PubMedAbstract available
BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in
HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977. PubMed
HUANG L, Zou L Letter to the Editor: Clinical outcomes and prognostic factors after HCV
clearance with DAA in HIV/HCV-coinfected patients with advanced
fibrosis/cirrhosis.
Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974. PubMed
BITTERMANN T, Yagan L, Kathawate RG, Weinberg EM, et al Real-world evidence for factors associated with maintenance treatment practices
among U.S. adults with autoimmune hepatitis.
Hepatology. 2024 Jun 12. doi: 10.1097/HEP.0000000000000961. PubMedAbstract available
TANG T, Li LQ, Wang ZD Baseline viral load in chronic hepatitis B may be clinically significant but must
be interpreted with caution.
Hepatology. 2024 Jun 6. doi: 10.1097/HEP.0000000000000956. PubMed
CORNBERG M, Wedemeyer H Early treatment of acute or recently acquired hepatitis C - an important tool on
the path to HCV elimination!
Hepatology. 2024 Jun 5. doi: 10.1097/HEP.0000000000000958. PubMed
HOWELL J, Hellard ME Reply: Provider preparedness for functional cure of chronic hepatitis B.
Hepatology. 2024;79:E160. PubMed
May 2024
WELTZSCH JP, Bartel CF, Waldmann M, Renne T, et al Optimizing thiopurine therapy in autoimmune hepatitis: A multi-center study on
monitoring metabolite profiles and co-therapy with allopurinol.
Hepatology. 2024 May 29. doi: 10.1097/HEP.0000000000000940. PubMedAbstract available
LIAO X, Fan R Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment
liver cancer risk: A multinational cohort study of HBeAg-positive patients.
Hepatology. 2024 May 28. doi: 10.1097/HEP.0000000000000942. PubMed
FENG Z Cathepsins prime hepatitis E virus for cell entry.
Hepatology. 2024 May 22. doi: 10.1097/HEP.0000000000000936. PubMed
POL S, Thompson AJ, Collins M, Venier E, et al Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment
of patients with acute hepatitis C: A single-arm retrospective study.
Hepatology. 2024 May 20. doi: 10.1097/HEP.0000000000000923. PubMedAbstract available
LO RE V 3RD, Price JC, Schmitt S, Terrault N, et al The obstacle is the way: Finding a path to hepatitis C elimination.
Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000807. PubMed
LUO C Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment
liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
Hepatology. 2024 May 14. doi: 10.1097/HEP.0000000000000928. PubMed
HALL EW, Bradley H, Barker LK, Lewis K, et al Estimating hepatitis C prevalence in the United States, 2017-2020.
Hepatology. 2024 May 13. doi: 10.1097/HEP.0000000000000927. PubMedAbstract available
KLOHN M, Burkard T, Janzen J, Haase JA, et al Targeting cellular cathepsins inhibits hepatitis E virus entry.
Hepatology. 2024 May 10. doi: 10.1097/HEP.0000000000000912. PubMedAbstract available
SHENOY A, Fontana RJ HDV screening in chronic HBV: An unmet need of growing importance.
Hepatology. 2024;79:979-982. PubMed
SEMMLER G, Mandorfer M The fade-out of HCV coinfection of people who live with HIV.
Hepatology. 2024 May 1. doi: 10.1097/HEP.0000000000000922. PubMed
April 2024
COLLIGNON L, Holmbeck K, Just A, Verhoye L, et al JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and
in vitro: Important tools in evaluation of virus neutralization.
Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000897. PubMedAbstract available
ZAHOOR MA, Feld JB, Lin HS, Mosa AI, et al Neutralizing antibodies to interferon alfa arising during peginterferon therapy
of chronic hepatitis B in children and adults: Results from the HBRN trials.
Hepatology. 2024 Apr 17. doi: 10.1097/HEP.0000000000000878. PubMedAbstract available
DUNN W, Li Y, Singal AK, Simonetto DA, et al An artificial intelligence-generated model predicts 90-day survival in
alcohol-associated hepatitis: A global cohort study.
Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000883. PubMedAbstract available
CHOI WM, Lim YS "Reply: Chronic hepatitis B baseline viral load and on-treatment liver cancer
risk: A multinational cohort study of HBeAg-Positive patients".
Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000884. PubMed
HE T, Zhang D Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment
liver cancer risk: A multinational cohort study of HBeAg-Positive patients.
Hepatology. 2024 Apr 12. doi: 10.1097/HEP.0000000000000882. PubMed
March 2024
ZHAO Q, Chen DP, Chen HD, Wang YZ, et al NK-cell-elicited gasdermin-D-dependent hepatocyte pyroptosis induces neutrophil
extracellular traps that facilitates HBV-related acute-on-chronic liver failure.
Hepatology. 2024 Mar 27. doi: 10.1097/HEP.0000000000000868. PubMedAbstract available
TIAN F, Forouzannia F, Feng Z, Biondi MJ, et al Feasibility of hepatitis C elimination by screening and treatment alone in
high-income countries.
Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000779. PubMedAbstract available
DIETZ-FRICKE C, Degasperi E, Jachs M, Maasoumy B, et al Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with
decompensated Child-B cirrhosis - a real world case series.
Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000847. PubMedAbstract available
BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV
coinfected patients with advanced Fibrosis/Cirrhosis.
Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838. PubMedAbstract available
PERRILLO RP, Janssen HLA Letter to the Editor: Provider preparedness for functional cure of chronic
hepatitis B.
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000810. PubMed
KONDILI LA, Craxi A Hepatitis C elimination: Tailoring the approach to each country's needs and
realities.
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000824. PubMed
GRATACOS-GINES J, Ruz-Zafra P, Celada-Sendino M, Marti-Carretero A, et al Recurrent alcohol-associated hepatitis is common and is associated with increased
mortality.
Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000825. PubMedAbstract available
February 2024
ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure
features a natural killer cell signature.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804. PubMedAbstract available
YAMAZAKI T, Kouno T, Hsu CL, Hartmann P, et al Serum aryl hydrocarbon receptor activity is associated with survival in patients
with alcohol-associated hepatitis.
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000777. PubMedAbstract available
PAPATHERODORIDIS G, Lampertico P Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients
under long-term nucleos(t)ide analogue therapy: New insights from Asia.
Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796. PubMed
MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ Editorial: Promise and pitfalls of a natural killer cell signature for
hepatocellular carcinoma detection in HCV patients with sustained virological
response.
Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797. PubMed
YU H, Shin EC Duet of humoral and cellular immunity for conquering hepatitis C virus.
Hepatology. 2024 Feb 9. doi: 10.1097/HEP.0000000000000769. PubMed
DIMOU A, Zachou K, Kostara C, Azariadis K, et al NMR-based metabolomic signature: An important tool for the diagnosis and to study
pathogenesis of autoimmune hepatitis.
Hepatology. 2024 Feb 5. doi: 10.1097/HEP.0000000000000767. PubMedAbstract available
January 2024
CHOI WM, Yip TC, Kim WR, Yee LJ, et al Chronic Hepatitis B baseline viral load and on-treatment liver cancer risk: A
multinational cohort study of HBeAg-Positive patients.
Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000752. PubMedAbstract available
Erratum: Antiviral therapy substantially reduces HCC risk in patients with
chronic hepatitis B infection in the indeterminate phase.
Hepatology. 2024 Jan 19. doi: 10.1097/HEP.0000000000000759. PubMed
GRIDLEY J, Holland B, Salinas E, Trivedi S, et al Concerted synergy between viral-specific IgG and CD8+ T cells is critical for
clearance of an HCV-related rodent hepacivirus.
Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000753. PubMedAbstract available
BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al Host genetic variation guides hepacivirus clearance, chronicity, and liver
fibrosis in mice.
Hepatology. 2024;79:183-197. PubMedAbstract available
December 2023
KINAST V, Todt D The relation of host genetics and symptomatic hepatitis E.
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000749. PubMed
JENG WJ, Chien RN, Liaw YF Reply: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis
B: A dangerous game?
Hepatology. 2023 Dec 27. doi: 10.1097/HEP.0000000000000737. PubMed
CHEN J, Tu T, Cohen C, Wang S, et al Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and
chronic hepatitis B: A dangerous game?
Hepatology. 2023 Dec 26. doi: 10.1097/HEP.0000000000000732. PubMed
YIP TC, Brunetto MR Hepatitis B surface antigen seroclearance is uncommon but durable in the long
run.
Hepatology. 2023 Dec 25. doi: 10.1097/HEP.0000000000000741. PubMed
SAADAT A, Gouttenoire J, Ripellino P, Semela D, et al Inborn errors of type I interferon immunity in patients with symptomatic acute
hepatitis E.
Hepatology. 2023 Dec 8. doi: 10.1097/HEP.0000000000000701. PubMedAbstract available
November 2023
SHEN J, Zhang K, Liu M, Wang T, et al Letter to the Editor: Alcohol-induced extracellular ASC specks perpetuate liver
inflammation and damage in alcohol-associated hepatitis even after alcohol
cessation.
Hepatology. 2023 Nov 28. doi: 10.1097/HEP.0000000000000682. PubMed
LEE J, Gil D, Park H, Lee Y, et al A multicellular liver organoid model for investigating hepatitis C virus
infection and non-alcoholic fatty liver disease progression.
Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000683. PubMedAbstract available
GISH RG, Jacobson IM, Lim JK, Waters-Banker C, et al Prevalence and characteristics of Hepatitis delta virus infection in patients
with hepatitis b in the united states: An analysis of the All-Payer Claims
Database.
Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000687. PubMedAbstract available
HE S, Peng Y, Wei Q Letter to the Editor: Lack of complete biochemical response in autoimmune
hepatitis leads to adverse outcome: First report of the IAIHG retrospective
registry.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000685. PubMed
SLOOTER CD, van den Brand FF, Lleo A, Liberal R, et al Reply - Lack of complete biochemical response in autoimmune hepatitis leads to
adverse outcome: first report of the IAIHG retrospective registry.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000689. PubMed
DE CARVALHO RIBEIRO M, Babuta M, Szabo G Reply: Alcohol-induced extracellular ASC specks perpetuate liver inflammation and
damage in alcohol-associated hepatitis even after alcohol cessation.
Hepatology. 2023 Nov 16. doi: 10.1097/HEP.0000000000000686. PubMed
BRUDEN D, McMahon BJ, Snowball M, Towshend-Bulson L, et al Rate and durability of clearance of hepatitis B surface antigen in Alaska Native
persons with long-term hepatitis B virus infection: 1982-2019.
Hepatology. 2023 Nov 7. doi: 10.1097/HEP.0000000000000658. PubMedAbstract available
LEE CH, Mak LY, Tang EH, Lui DT, et al SGLT2i reduces risk of developing HCC in patients with co-existing type 2
diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong.
Hepatology. 2023;78:1569-1580. PubMedAbstract available
October 2023
JENG WJ, Chien RN, Liaw YF Reply: Cautious interpretation of the association between finite treatment and
better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis.
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000662. PubMed
DENG R, Wang Z, Liu Y, Sun J, et al Letter to the Editor: Cautious interpretation of the association between finite
treatment and better prognosis in initially HBeAg-negative hepatitis B patients
with cirrhosis.
Hepatology. 2023 Oct 31. doi: 10.1097/HEP.0000000000000654. PubMed
GISH RG, Wong RJ, Di Tanna GL, Kaushik A, et al Association between hepatitis delta virus with liver morbidity and mortality: A
systematic literature review and meta-analysis.
Hepatology. 2023 Oct 23. doi: 10.1097/HEP.0000000000000642. PubMedAbstract available
DONGELMANS EJ, Sonneveld MJ, Janssen HLA Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B
patients, true effect or residual confounding?
Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000639. PubMed
LIAW YF, Jeng WJ, Chien RN Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true
effect or residual confounding?
Hepatology. 2023 Oct 20. doi: 10.1097/HEP.0000000000000641. PubMed
ELSHEIKH R, Makram AM, Huy NT Reply: Outbreak of indeterminate acute hepatitis in children, not a new disease
but an epidemiological phenomenon.
Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000625. PubMed
JAGADISAN B, Dhawan A Letter to the Editor: Outbreak of indeterminate acute hepatitis in children, not
a new disease but an epidemiological phenomenon.
Hepatology. 2023 Oct 9. doi: 10.1097/HEP.0000000000000622. PubMed
September 2023
CHOLANKERIL G, Vierling JM The clinical imperative of a complete biochemical response to immunosuppression
in autoimmune hepatitis: Close is not good enough!
Hepatology. 2023 Sep 18. doi: 10.1097/HEP.0000000000000597. PubMed
SLOOTER CD, van den Brand FF, Lleo A, Colapietro F, et al Lack of complete biochemical response in autoimmune hepatitis leads to adverse
outcome: first report of the IAIHG retrospective registry.
Hepatology. 2023 Sep 4. doi: 10.1097/HEP.0000000000000589. PubMedAbstract available
GILL US, Peppa D Pegylated interferon-alpha for chronic hepatitis B...not ready to be shelved yet! new
insights on its role using single-cell transcriptomics.
Hepatology. 2023 Sep 1. doi: 10.1097/HEP.0000000000000560. PubMedAbstract available
May 2023
TONON M, Balcar L, Semmler G, Calvino V, et al Etiological cure prevents further decompensation and mortality in cirrhotic
patients with ascites as the single first decompensating event.
Hepatology. 2023 May 17. doi: 10.1097/HEP.0000000000000460. PubMedAbstract available
April 2023
KUM DB, Vanrusselt H, Acosta Sanchez A, Taverniti V, et al Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through
core-dependent hepatocyte death and proliferation.
Hepatology. 2023 Apr 28. doi: 10.1097/HEP.0000000000000428. PubMedAbstract available
January 2023
CUNNINGHAM M, Gupta R, Butler M Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000045. PubMedAbstract available